You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
之江生物(688317.SH)2020年度淨利潤預增1705.10%左右
格隆匯 01-27 16:22

格隆匯 1 月 27日丨之江生物(688317.SH)公佈,經財務部門初步測算,預計公司2020年年度實現歸屬於母公司所有者的淨利潤93002.14萬元左右,與上年同期(法定披露數據)相比,將增加87849.96萬元左右同比增加1705.10%左右;歸屬於母公司所有者的扣除非經常性損益的淨利潤92771.97萬元左右,與上年同期(法定披露數據)相比,將增加88339.5萬元左右,同比增加1993.01%左右。

2020年度,全球範圍內暴發新冠肺炎疫情。公司作為首批獲得新冠病毒核酸檢測試劑盒註冊證的企業,新冠核酸檢測試劑盒銷售規模取得了重大業績突破,同時也帶動了分子診斷儀器、核酸提取試劑等其他相關係列產品的增量銷售,促使公2020年度整體銷售規模呈現大幅增長。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account